Problem: The Malaita and Western provinces in Solomon Islands had low routine immunization coverage due to disruptions in health services caused by the coronavirus disease 2019 pandemic in early 2022.
Approach: The country introduced the World Health Organization (WHO) Reaching Every District (RED) approach in 2002. Between July and September 2022, we strengthened supportive supervision, monitoring and use of data for decision-making, especially for microplanning and re-establishing outreach to prioritized areas. Health workers were supported to identify key concerns and develop strategies to improve performance. Monthly updates of reported immunization coverage, reporting completeness and fieldwork findings were widely disseminated.
Local Setting: Solomon Islands' population is 748 606 people, of whom 165 345 reside in Malaita and 105 367 in Western Province.
Relevant Changes: In Malaita Province, reported coverage of third dose of pentavalent vaccine and first dose of measles-rubella vaccine increased from 40% (757/1892) of eligible children to 121% (1144/946) and from 30% (568/1892) to 159% (1504/946), respectively; and in Western Province reported coverage increased from 38% (443/1165) to 191% (1113/583) and from 44% (513/1165) to 149% (868/583), respectively. Reported coverage for the remaining provinces increased from 64% (3380/5282) to 88% (2325/2641) and from 59% (3116/5282) to 137% (3619/2641), respectively. These findings led the programme on immunization to re-expand the WHO RED approach nationwide.
Lessons Learnt: Supportive supervision, systematic monitoring and use of data for decision-making helped restoring reported immunization coverage in two low-coverage provinces. However, sustaining these results at a national level is necessary. The WHO RED approach remains relevant, even during a pandemic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418846 | PMC |
http://dx.doi.org/10.2471/BLT.24.291084 | DOI Listing |
Enferm Infecc Microbiol Clin (Engl Ed)
January 2025
Centro Nacional de Gripe de Valladolid (GISRS/WHO), Spain. Electronic address:
Despite high initial vaccination rates, Spain's current COVID-19 vaccination coverage in recommended groups does not meet WHO targets. For the upcoming season, challenges include revising vaccination age, updating risk groups, and unifying criteria with flu vaccine co-administration. European Commission's advance purchase agreements limit access to certain vaccines, and the need for vaccines effective against current variants adds administrative complexities.
View Article and Find Full Text PDFVaccine
January 2025
Maternité Port-Royal, Groupe hospitalier Paris Centre, AP-HP, FHU Prema, 75014 Paris, France; Université Paris Cité, Paris, France; INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epopé), Center for Epidemiology and Statistics, Université de Paris-Cité, Paris, France.
Background: Despite French national recommendations since 2012 that all pregnant women be vaccinated against influenza, in 2021 this vaccine coverage is low - around 30 % - in France.
Objectives: To identify barriers to influenza vaccination during pregnancy by assessing how often women were offered this vaccination and how often they accepted it.
Study Design: We used data from the French national perinatal survey (ENP), which covered all births during one week in March 2021 (N = 12,614).
PLoS One
January 2025
The Department of Disease Control and Prevention, Shandong Armed Police Forces General Hospital, Jinan, China.
Introduction: Vaccination is an important way to prevent disease, but vaccine hesitancy will impact vaccine coverage and indirectly affect health. This study aims to survey the status of vaccine hesitancy among adults in Jinan.
Methods: A cross-sectional study was conducted using the vaccine hesitancy scale among the parents of children and teenagers at hospitals in Jinan, China.
Hum Vaccin Immunother
December 2025
GSK, Verona, Italy.
Rotavirus, a leading cause of severe acute gastroenteritis in children, is largely preventable through immunization with two internationally licensed oral rotavirus vaccines (RVVs) included in national programs across over 100 countries. These RVVs are administered in either two (Rotarix™; 2D-RV) or three (RotaTeq®; 3D-RV) doses. We aimed to assess the global coverage, completion, and compliance of 2D-RV and 3D-RV in various settings, and to identify factors influencing vaccine coverage.
View Article and Find Full Text PDFPublic Health Rep
January 2025
Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!